Dr Michael Keating completed his PhD jointly in the Lipid Metabolism and Cardiometabolic Disease, and the Molecular Metabolism and Aging laboratories at the Baker Institute in 2020. During his PhD studies his research focused on the discovery and characterisation of novel regulators of hepatic lipid metabolism.

Currently, Michael holds a postdoctoral position at the Baker Institute. His work involves identifying novel targets that may regulate hepatic lipid metabolism and then assessing if they have the potential to be of therapeutic benefit to humans with cardiometabolic diseases. Most recently he has worked to setup a preclinical CRISPR validation platform with an aim to streamline target section and translatability. His work has published in high impact journals including Nature and Circulation Research.